News - EGFR E709K - LARVOL VERI

9ms

NCI-2019-05913: Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer (clinicaltrials.gov)

P1, N=22, Active, not recruiting, Collin Blakely | Recruiting --> Active, not recruiting | N=38 --> 22 | Trial completion date: Feb 2025 --> May 2025 | Trial primary completion date: Feb 2025 --> May 2025

9 months ago

Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases

EGFR (Epidermal growth factor receptor) • TPX2 (TPX2 Microtubule Nucleation Factor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L

Tagrisso (osimertinib) • alisertib (MLN8237)

1year

NCI-2019-05913: Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer (clinicaltrials.gov)

P1, N=38, Recruiting, Collin Blakely | Trial completion date: Dec 2023 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Feb 2025

1 year ago

Trial completion date • Trial primary completion date • Combination therapy • Metastases

EGFR (Epidermal growth factor receptor) • TPX2 (TPX2 Microtubule Nucleation Factor)

Tagrisso (osimertinib) • alisertib (MLN8237)

over1year

Concordance of Actionable Mutations in Liquid Biopsies and Matched Tumor Tissue of Brazilian Non-small Cell Lung Cancer (NSCLC) (LALCA 2023)

The NGS panel could successfully detect actionable mutations in liquid biopsies with a high concordance rate and sensitivity. The detection of variants in cfDNA, but not in tDNA, suggests a greater representativeness of the mutational tumor spectrum in samples of liquid biopsies opening perspectives for employing this approach in the routing setting. The NGS assay for liquid biopsy may decrease tissue biopsies and turnaround time for report release, accelerating therapeutic strategies for NSCLC patients.

over 1 year ago

Liquid biopsy • Biopsy • Discordant

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MAP2K1 (Mitogen-activated protein kinase kinase 1)

KRAS G12C • EGFR T790M • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12 • PIK3CA E542K • KRAS G13 • TP53 R175H • KRAS Q61H • ALK R1275Q • BRAF G469A • EGFR E709K • MAP2K1 P124Q • PIK3CA E542 • TP53 R248Q • TP53 Y220C • EGFR E746 • MAP2K1 E203K • MAP2K1 P124 • TP53 R273C

Oncomine™ Lung cfDNA Assay

over1year

UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN). (PubMed, J Thorac Oncol)

Osimertinib demonstrated activity in ucEGFRmut with high rate of disease control systemically and intracranially. Several resistance mechanisms were identified. This report comprises, to the best of our knowledge, the largest dataset of its kind.

over 1 year ago

Journal

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase)

TP53 mutation • EGFR mutation • PIK3CA mutation • MET amplification • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR C797S • EGFR G719X • MET mutation • EGFR exon 20 mutation • EGFR mutation + PIK3CA mutation • EGFR E709K

Tagrisso (osimertinib)

2years

NCI-2019-05913: Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer (clinicaltrials.gov)

P1, N=38, Recruiting, Collin Blakely | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2023

2 years ago

Trial completion date • Trial primary completion date • Combination therapy

EGFR (Epidermal growth factor receptor) • TPX2 (TPX2 Microtubule Nucleation Factor)

Tagrisso (osimertinib) • alisertib (MLN8237)

2years

TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study. (PubMed, Asian Pac J Cancer Prev)

TP53 and EGFR mutations were not most frequent, so it seems that these genes are not involved in the pathogenesis of thymoma in Indonesian patients. Nevertheless, we found two samples with a significant mutation in p53 and EGFR genes, suggesting further research on thymoma prognostification and targeted therapy.

2 years ago

Journal

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)

TP53 mutation • EGFR mutation • EGFR exon 18 mutation • EGFR E709K • TP53 exon 6 mutation

almost3years

NCI-2019-05913: Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer (clinicaltrials.gov)

P1, N=38, Recruiting, Collin Blakely | Trial completion date: Sep 2024 --> May 2023 | Trial primary completion date: Sep 2022 --> May 2023

almost 3 years ago

Trial completion date • Trial primary completion date • Combination therapy

EGFR (Epidermal growth factor receptor) • TPX2 (TPX2 Microtubule Nucleation Factor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR V834L

Tagrisso (osimertinib) • alisertib (MLN8237)

4years

A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies (clinicaltrials.gov)

P2, N=150, Recruiting, Spectrum Pharmaceuticals, Inc | Not yet recruiting --> Recruiting

4 years ago

Clinical • Enrollment open

EGFR (Epidermal growth factor receptor)

EGFR mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR T790M • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • HER-2 S310F • HER-2 V777L • EGFR E709K • HER-2 I655V • HER-2 L869R • HER-2 V842I • EGFR P596L • EGFR R222C • HER-2 T798M • EGFR E746 • HER-2 D769H • HER-2 R678Q • HER-2 T798I • HER-2 mutation + HER-2 T798I • EGFR V774M

Pozenveo (poziotinib)